Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

NCT01321554 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01321554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 17, 2011
Completion date
March 19, 2019
Enrollment
392 (actual)
Sites
155

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer